Plasma S100A12 levels and peripheral arterial disease in end-stage renal disease.
Plasma S100A12 levels and peripheral arterial disease in end-stage renal disease.
复制标题
DOI：
10.1159/000335198
复制
发表时间：
2011-01
期刊：
影响因子：
--
通讯作者：
Kosaki A
中科院分区：
文献类型：
--
作者：
Shiotsu Y;Mori Y;Hatta T;Maki N;Iida K;Matsuoka E;Kado H;Ishida R;Kishimoto N;Tamagaki K;Nishimura M;Iwamoto N;Ono T;Matsubara H;Kosaki A
S100A12是晚期糖基化终产物受体(RAGE)的内源性配体。终末期肾病(ESRD)维持性血液透析(HD)患者血浆S100A12水平升高。外周动脉疾病(PAD)在HD患者中很常见，并与这一人群中心血管发病率和死亡率的增加有关。然而，到目前为止，还没有研究专门评估HD患者血浆S100A12与PAD的关系。我们在附属医院对152例HD患者进行了横断面研究。我们调查了PAD病史和患者特征，并量化了所有参与者的血浆S100A12水平。有PAD的HD患者(n=26；21.9[13.6~33.4]ng/ml)血浆S100A12水平显著高于无PAD的HD患者(n=126；11.8[7.5~17.6]ng/ml；P<0.001)。在多因素Logistic回归分析中，血浆S100A12水平(优势比[OR]5.71；95%可信区间[CI]1.29~25.3；p=0.022)被确定为PAD患病率的独立相关因素。与PAD患病率相关的另一个因素是踝臂指数(OR0.54；95%CI0.40-0.74；p<；0.001)。这些结果表明，血浆S100A12水平与终末期肾病HD患者的PAD患病率密切相关。
S100A12 is an endogenous ligand of the receptor for advanced glycation end products (RAGE). Plasma S100A12 levels are high in end-stage renal disease (ESRD) patients undergoing maintenance hemodialysis (HD). Peripheral arterial disease (PAD) is common in HD patients and is associated with increased cardiovascular morbidity and mortality rates in this population. To date, however, no study has specifically assessed the relationship between plasma S100A12 and PAD in HD patients. We conducted a cross-sectional study of 152 HD patients in our affiliated hospital. We investigated PAD history and patient characteristics and quantified plasma S100A12 levels in all participants. HD patients with PAD (n = 26; 21.9 [13.6–33.4] ng/ml) showed significantly higher plasma S100A12 levels than HD patients without PAD (n = 126; 11.8 [7.5–17.6]ng/ml; p < 0.001). In multivariate logistic regression analysis, the plasma S100A12 level (odds ratio [OR] 5.71; 95% confidence interval [CI] 1.29–25.3; p = 0.022) was identified as an independent factor associated with PAD prevalence. Another factor associated with PAD prevalence was the ankle-brachial index (OR 0.54; 95% CI 0.40–0.74; p < 0.001). These results suggest that plasma S100A12 levels are strongly associated with PAD prevalence in ESRD patients undergoing HD.